The Thermo Scientific OncoInsight Program – Integrating Best-In-Class Technologies to provide Deeper Insights for Oncology Research

The Thermo Scientific OncoInsight Program offers the first integrated assay platform for accelerating oncology research, through deeper insights into cancer cell biology. Combining our expertise in advanced image cytometry technologies and innovative reagents, the OncoInsight* program offers customers the ability to rapidly assay key cellular oncology targets.

At the core of this program is the Thermo Scientific CellInsight Personal Image Cytometer which provides the oncology researcher with a simple-to-operate, low-cost, bench top automated imaging capability for cell assays. The CellInsight Personal Image Cytometer uses the latest Thermo Scientific iDEV workflow software for rapid cell assay development broad assay flexibility for hundreds of biologies.

The OncoInsight program offers researchers innovative assay formats for oncology, such as simple mix-and-read assays, which use GFP-tagged proteins stably expressed in cells to track intracellular protein translocation. These assay targets are selected based on research to understand the molecular structure of drug receptors, the specific biochemical characteristics of intracellular proteins, the unique products of aberrant genes, and the cellular process underlying the cause of cancer. Thermo Fisher Scientific offers single targets or panels of related targets for screening or selective studies. Flexible pricing options are available depending on the number of targets selected. A wide variety of oncology targets are available in the OncoInsight program such as:

• Akt1 • FOXO4/AFX
• Akt1-PH • ERF1 T24
• Akt2 • ERF1 U2OS
• Akt3 • Hexokinase II
• Btk-PH • HIF-1alpha
• FKHR • PDK1
• FKHRL1 • Ras
• Rac1 • EGFR
• and more


Thermo Scientific HCSonDemand managed services offer complete assay development solutions to accelerate cancer research and discovery. HCSonDemand* services offer clients scientific expertise using the most advanced assay reagents, assay technologies and instrumentation. At the core of HCSOnDemand Services lies our expertise in developing and running multiplexed imaging assays used to quantitatively monitor the cellular changes in cells after drug treatments. Researchers can take advantage of HCSonDemand services to test the feasibility of adopting higher-content cell assays, run a complete screen of compounds for oncology targets or develop a new multiplexed imaging assay for cancer research

The OncoOnsight Program is available now and will be demonstrated at AACR, April 2-6, 2011 at Booth #511. For more information visit the Company Article Page.